Osteosarcoma, Spindle Cell Sarcoma of Bone
Conditions
Brief summary
The study is a first step of a process to establish the standard chemotherapy treatment with the aim to improve outcome for patients with these rare tumours. For this reason the study will be non-controlled clinical trial. In this regard, the study aims to determine the feasibility of intensive chemotherapy in this age group, and/or separate efficacy analyses according to the different histologic categories and whether the number of patients recruited by the co-operating groups permits future randomised studies.
Detailed description
Wide surgical removal of the tumor with the addition of a systemic treatment based on the antineoplastic drugs active against osteosarcoma (Adriamycin, Cisplatin, Ifosfamide, Methotrexate). The use of radiation therapy will be given to patients with unresectable tumors. It is recommended in patients who underwent inadequate surgical removal of the tumor. The addition of radiation therapy can not compensate for an adequate surgical treatment. All the patients eligible for the study will receive the planned systemic treatment. Depending on clinical features, and feasibility of adequate surgical removal of the tumor, patients may receive primary chemotherapy followed by a postoperative chemotherapy treatment or only an adjuvant chemotherapy. In case of immediate surgery, patients will receive an adjuvant treatment with the 3-drug regimen (Cisplatin-Adriamycin-Ifosfamide).
Interventions
DRUGDoxorubicin+cisplatin+ifosfamide
Chemotherapy for Good responder high grade osteosarcoma
DRUGDoxorubicin+cisplatin+ifosfamide+methotrexate
Chemotherapy for Poor responder high grade osteosarcoma
Sponsors
Scandinavian Sarcoma Group
Cooperative Osteosarcoma Study Group
Italian Sarcoma Group
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
41 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically proven diagnosis of high-grade sarcoma of bone of any site. 2. Histologic types: osteosarcoma (high-grade surface, central primary and secondary), fibrosarcoma, malignant fibrous histiocytoma, leiomyosarcoma, dedifferentiated chondrosarcoma, angiosarcoma. 3. Age: 41 - 65 4. Normal bone marrow, hepatic, cardiac and renal function 5. Absence of contraindications to the use of cisplatin, adriamycin, and ifosfamide 6. Written informed consent
Exclusion criteria
1. Planned chemotherapy and/or follow-up not feasible 2. Previous chemotherapy treatment, which contraindicates the use of one or more drugs, included in the present protocol 3. Previous chemotherapy treatment for the current tumor 4. White blood count \< 3.0 x 109/L, and platelets \< 100 x 109/L 5. Creatinine clearance \< 70 ml/min 6. Left ventricular ejection fraction \< 55% or fractional shortening rate of the left ventricle \<28% 7. Serum transaminases and bilirubin \> 2 times the normal values 8. ECOG performance status \> 2 9. Chondrosarcoma or small/round cell bone sarcoma including mesenchymal chondrosarcoma and Ewing's family tumors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival | from the date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 168 months. | Survival without any events related to disease (e.g: progression, relapse or osteosarcoma related death) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | from the date of randomization until the date of first documented progression of disease, whichever came first, assessed every 6 months, up to 168 months | Survival without progression of disease |
| Disease-free survival | from the date of randomization until the date of first documented progression of disease, whichever came first, assessed every 6 months, up to 168 months | Survival without disease |
| Metastasis-free survival | from the date of randomization until the date of first documented progression in term of metastasis, whichever came first, assessed every 3 months, up to 168 months | Survival without metastasis |
| Overall survival | from the date of randomization until the end of the study, assessed every 3 months, up to 168 month | Global patients survival evaluation after treatment |
| Chemotherapy toxicity | Every 3 weeks | Number and grade of adverse events related to the study treatments |
Countries
Germany, Italy, Sweden
Outcome results
None listed